Immunotherapy combination improves survival for patients with unresectable malignant pleural mesothelioma
In short: A phase 3 clinical trial involving 605 patients found that combining the drugs nivolumab and ipilimumab significantly extended overall survival compared to standard chemotherapy for those with untreated, unresectable malignant pleural mesothelioma.
Researchers conducted this multicentre, randomised trial across 103 hospitals to test if immunotherapy could outperform traditional chemotherapy regimens.
The study found that the immunotherapy combination extended median overall survival to 18.1 months, compared to 14.1 months for chemotherapy. However, the trial was open-label, meaning both patients and clinicians knew which treatment was being administered.
Why it matters: Immunotherapy may offer a more effective first-line treatment option for unresectable malignant pleural mesothelioma than standard chemotherapy.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Baas et al. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet (London, England).
To cite this card, link to https://intellectplus.co.uk/app/health-research-immunotherapy-combination-improves-survival-for-patients-wit.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health · Latest · A–Z · All topics
